Will AngioDynamics Beat These Analyst Estimates?
AngioDynamics (NAS: ANGO) is expected to report Q3 earnings on April 8. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AngioDynamics's revenues will grow 60.9% and EPS will compress -44.4%.
The average estimate for revenue is $83.0 million. On the bottom line, the average EPS estimate is $0.05.
Last quarter, AngioDynamics booked revenue of $87.0 million. GAAP reported sales were 50% higher than the prior-year quarter's $58.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.10. GAAP EPS of $0.06 for Q2 were 33% lower than the prior-year quarter's $0.09 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 50.7%, 650 basis points worse than the prior-year quarter. Operating margin was 8.1%, 80 basis points worse than the prior-year quarter. Net margin was 2.3%, 170 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $340.9 million. The average EPS estimate is $0.33.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 99 members out of 114 rating the stock outperform, and 15 members rating it underperform. Among 31 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 27 give AngioDynamics a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AngioDynamics is outperform, with an average price target of $13.50.
Is AngioDynamics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
Add AngioDynamics to My Watchlist.
The article Will AngioDynamics Beat These Analyst Estimates? originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.